Across TCGA pan-cancer cohorts, RPL21P37 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RPL21P37 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPL21P37 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL21P37 expression acts as an unfavorable survival marker.

OV are the cancer types where RPL21P37 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.076	0.844	<.001	48	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RPL21P37 tumor-vs-normal RNA expression · all RPL21P37 data types